PIVOT3
Pivot3 , a pioneer and innovator in the development of hyper-converged infrastructure (HCI), today announced it will bring its HCI technology to VMware vSphere® 6.
VMware vSphere 6 is the industry-leading virtualization platform for the hybrid cloud and the foundation for the software-defined data center. VMware vSphere 6 provides customers with a highly available, resilient, on-demand cloud infrastructure to run, protect and manage any application.
The newest edition of Pivot3’s patented vSTAC OS software, vSTAC OS 7 which uses patented Scalar Erasure Coding technology, is now built on a foundation of VMware vSphere 6 which enables GPU virtualization, higher fault tolerance and greater availability on Pivot3’s HCI platforms.
The upcoming release of the vSTAC OS Management Client Integration Plug-In integrates with the VMware vSphere 6 Web Client interface to enable users to manage their entire Pivot3 hyper-converged array of nodes which scales to petabytes of storage and millions of Input/Output Operations Per Second (IOPS) – all from a central console.
Pivot3’s global hyper-converged infrastructure solution helps enterprises achieve low total cost of ownership by providing combined virtualized shared storage and compute power on the same platform, eliminating the need for separate physical storage area networks (SANs) and servers. The streamlined vSTAC OS 7 dashboard provides VMware server administrators and application owners with an easy-to-manage status view and control console for the combined Pivot3 virtual SAN and compute environment.
“Pivot3’s HCI provides the performance and high-availability of shared storage without the need for expensive external storage arrays,” said Ron Nash, CEO of Pivot3. “With Pivot3 global HCI, growing enterprises and organizations with multiple locations, such as remote or branch offices (ROBOs), can deploy critical applications and associated data onsite so that they are available at all times without needing access to company-wide networks.”
Pivot3 also supports End User Computing (EUC) licensing of VMware Horizon® 6 for desktop virtualization. VMware Horizon provides end-users access to all of their virtual desktops, applications and online services through a single workspace.
“Pivot3’s HCI with VMware vSphere 6 provides enterprise customers with a scale-out, distributed storage architecture,” said Howard Hall, senior director, Global Technology Partner Organization, VMware. “Pivot3's efficient, high-performance infrastructure combining storage and compute capabilities with VMware vSphere can accelerate time to value for organizations, which means that they can now deploy their solution much faster with less specialized expertise, all at a lower cost. The result is that customers can benefit from increased CPU power to more efficiently run advanced VMware vSphere 6 features.”
Pivot3, with its efficient and scalable HCI, has been a VMware supporter since 2008. The immediate support for VMware vSphere 6 builds on Pivot3’s longstanding partnership with VMware, which includes support for VMware Horizon and VMware Mirage™, as well as 100 percent reliance on VMware vSphere.
Pivot3 has 1,600 customers around the world. Enterprise customers who buy Pivot3 HCI also buy Enterprise and Enterprise Plus licenses from VMware. Pivot3 is also an Original Equipment Manufacturer (OEM) and Technology Alliance Partner, and is a top tier sponsor of VMware User Group and VMware vForum.
About Pivot3
Founded in 2002, Pivot3 provides patented global hyper-convergence technology that saves an extraordinary amount of space, ensures fault tolerance, drives down complexity and cost and dramatically increases scale-out performance. Today, Pivot3 has more than 1,600 customers around the world deploying more than 13,000 globally hyper-converged infrastructure appliances in multiple industries, such as video surveillance, healthcare, government, transportation, entertainment, education, gaming and retail. The company has won numerous awards and was most recently featured by CRN in their top 50 Virtualization list for 2014. To learn more about Pivot3, visit http://www.pivot3.com .
VMware, vSphere, Horizon, and Mirage are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions. The use of the word “partner” or “partnership” does not imply a legal partnership relationship between VMware and any other company.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151012006212/en/
Contact:
for Pivot3
Allison Francis, 972-235-3439
afrancis@ideagrove.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom